Understanding the biology of triple-negative breast cancer
Open Access
- 1 August 2012
- journal article
- review article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 23 (suppl_6), vi13-vi18
- https://doi.org/10.1093/annonc/mds188
Abstract
Greater understanding of the biology of triple-negative breast cancer (TNBC) is needed to discern the roughly 60% of node-negative patients who are already cured with locoregional therapy from the 40% who need adjuvant systemic therapy to be cured. Recent evidence suggests that patients with TNBC whose tumours have an activated immune response gene signature have a more favourable outcome than TNBC patients without this signature. For the group who needs additional systemic therapy, the challenge remains to choose the right systemic drug combination for the right TNBC sub-type. Significant heterogeneity exists within the TNBC class that is exemplified by differing chemotherapeutic sensitivity observed for some sub-types. This heterogeneity establishes the need for identifying differentiating molecular markers within the overall class of TNBC disease, which may help refine therapeutic management. In this review, we discuss some of these promising predictive molecular markers for tailoring therapy. In addition, several gene expression profiling and functional studies employing genetic screens that help to establish TNBC sub-groups with varying sensitivities to a variety of targeted therapies currently under clinical investigation are conferred. It is anticipated that a greater understanding of the biology of TNBC and its complex heterogeneity will reveal novel targets or identify markers around which clinical trials in molecularly well-defined sub-groups can be designed.Keywords
This publication has 51 references indexed in Scilit:
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression ProfilingClinical Cancer Research, 2012
- Clinical relevance of TNM staging system according to breast cancer subtypesAnnals Of Oncology, 2011
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 StudiesPLoS Medicine, 2010
- Management of triple negative breast cancerThe Breast, 2010
- Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancerAnnals Of Oncology, 2010
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GABreast Cancer Research and Treatment, 2008
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Molecular portraits of human breast tumoursNature, 2000